Investing.com — AstraZeneca (LON:) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration.
The drug is the first inhibitor of its type to be authorized in the world’s largest health market, BioPharmaceuticals Business Unit head Ruud Dobber said in a press release. There are an estimated 30 million people living with type-2 diabetes in the US, and heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.
AstraZeneca shares are up 15% so far this year
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.